THERAPY DOSSIER · th-9fee9f038c90

Ghrelin combined with pegylated G-CSF

Hormone · Ghrelin (peptide hormone) combined with pegylated G-CSF.

Evidence & regulatory context

Mechanism: Ghrelin (peptide hormone) combined with pegylated G-CSF.
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 34368440 ↗2019Reported benefit

A novel therapy, using Ghrelin with pegylated G-CSF, inhibits brain hemorrhage from ionizing radiation or combined radiation injury.

MouseRadiationB6D2F1/JFemaleSubcutaneous for both, in 0.2 mLGhrelin 113 micrograms/kg; pegylated G-CSF 1000 micrograms/…First doses 24 h after irradiation or combined injury

Model: 9.5 Gy whole-body cobalt-60 gamma irradiation alone, or followed within 1 h by a 15% total body surface area skin wound

Ghrelin with pegylated G-CSF reduced brain haemorrhage after radiation and combined injury, restored platelet counts, ghrelin receptors, ATP and phospho-AKT, and lowered active caspase-3.

Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.

Loading the evidence…